알림
뒤로

보도자료

회사뉴스 게시판

Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea

회사뉴스
2020-05-07
조회수 969

Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea


0
빅씽크, 美푸마와 '네라티닙' 국내 도입 계약
목록

Copyright 2021 - BIXINK   │   Terms of Use   │   Contact   │   Privacy

서울특별시 강남구 강남대로 292 6층 [06258]

6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258, Republic of Korea